explore -WSS

explore

author：focus 2025-09-06 03:16:43 - browse：82212

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： The (many) problems with a new study criticizing cancer screening

WSS

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

Weighted lottery helped low

What American doctors can learn from their Israeli counterparts

The (many) problems with a new study criticizing cancer screening

Amazon on where the company's health care bets are headed next

Taylor Swift shares sweet moment with Kobe Bryant's daughter Bianka at Eras Tour concert

knowledge

explore

hotspot

Drug repurposing or repositioning? The language matters

Advances in CAR

Heart attack and stroke risk calculators need revising

The 10 drugs up first for Medicare price negotiation

Apple is now the first public company to be valued at $3 trillion

Snackable artificial intelligence, expert AI, and the pharma industry

As demand for Covid shots wanes, Moderna seeks its next success

Humana sues Biden admin over Medicare Advantage audit rule

Anesthesiologist group: stop taking Ozempic before surgery

Why Novartis is changing the name of its research labs

focus

Eat, drink, but be wary — 4 foods that interact with medications

Snackable artificial intelligence, expert AI, and the pharma industry

NIH nominee Bertagnolli will get October confirmation hearing

Rivals hope for voter 'fatigue' as Trump's woes mount but base stays loyal: ANALYSIS

AstraZeneca chief proposes a novel edit to the drug pricing bill

Medicaid rebukes states for mistakenly disenrolling children

hotspot

leisure time

focus

focus